You Position: Home > Paper
弥漫大B细胞淋巴瘤基于分子遗传学特性的分层治疗策略
( views:239, downloads:136 )
- Author:
- No author available
- Journal Title:
- Journal of Leukemia & Lymphoma
- Issue:
- 9
- DOI:
- 10.3760/cma.j.issn.1009-9921.2011.09.002
- Key Word:
- 弥漫大B细胞淋巴瘤;分子遗传学;分层治疗
Abstract： No abstract available
- [1]Motohiro Kato,Masashi Sanada,Itaru Kato,etc.Frequent inactivation of A20 in B-cell lymphomas[J].2009,459(Jun.4 TN.7247).
- [2]Levy R,Lossos IS,Czerwinski DK,etc.Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.[J].2004,350(18).
- [3]Dalla-Favera R,Klein U.Germinal centres: role in B-cell physiology and malignancy.[J].2008,8(1).
- [4]Mara, Compagno,Wei Keat, Lim,Adina, Grunn,etc.Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.[J].2009,459(7247).
- [5]Davis RE,Brown KD,Siebenlist U,etc.Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.[J].2001,194(12).
- [6]Brahmachary M,Tang H,Mo T,etc.BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma.[J].2010,18(6).
- [7].Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma[J].2010,463(Jan.7 TN.7277).
- [8]Pfreundschuh M,Trumper L,Osterborg A,etc.CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.[J].2006,7(5).
- [9]Dunleavy K,Pittaluga S,Czuczman MS.Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.[J].2009,113(24).
- [10]N L, Harris,E S, Jaffe,H, Stein,etc.A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.[J].1994,84.
- [11].A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.[J].1997,89.
- [12]Wilson WH,Little RF,Pittaluga S,etc.The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.[J].2010,115(15).
- [13]Ruan J,Martin P,Furman RR,etc.Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.[J].2011,29(6).
- [14]O'Connor OA,Czuczman MS,Humerickhouse RA,etc.Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.[J].2010,11(12).
- [15]W H, Wilson,J, Teruya-Feldstein,T, Fest,etc.Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas.[J].1997,89.
- [16]Masumichi Saito,Jie Gao,Katia Basso.A Signaling Pathway Mediating Downregulation of BCL6 in Germinal Center B Cells Is Blocked by BCL6 Gene Alterations in B Cell Lymphoma[J].2007,12(3).